• Passa al contenuto principale
BC

biochimica clinica

it_IT Italian
it_IT Italian en_US English
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

DOCUMENTI SIBIOC - SIBioC Documents

Volume:

Biochimica Clinica 2019; 43(3) 327-331

Pubblicato on-line:

Marzo 7, 2019

DOI:

10.19186/BC_2019.010

Scarica in PDF:
Autenticazione richiesta

Interferenza da biotina negli immunodosaggi: raccomandazioni del Gruppo di Studio SIBioC sulla Variabilità Extra-Analitica (SIBioC-VEA)

AUTORI

Giuseppe Lippi1,2, Graziella Bonetti1,3, Annalisa Modenese1,4, Andrea Padoan1,5, Davide Giavarina1,6, per il GdS SIBioC sulla Variabilità Extra-Analitica (SIBioC-VEA)
1Gruppo di Studio sulla Variabilità Extra-Analitica (SIBioC-VEA)
2 Sezione di Biochimica Clinica, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italia
3 Laboratorio Centrale di Chimica Clinica, ASST – Spedali Civili, Brescia, Italia
4 Istituto Clinico Città Studi (ICCS) Milano, Italia
5 Dipartimento Strutturale Medicina di Laboratorio, Azienda Ospedale Università di Padova, Italia
6 Dipartimento della Diagnostica, Laboratorio Analisi, Ospedale San Bortolo, Vicenza, Italia

ABSTRACT

Biotin interference in immunoassays: recommendations of the SIBioC Working Group on Extra-AnalyticalVariability (WG-VEA).

Biotin is a water-soluble vitamin, which participates to a vast array of metabolic pathwaysinvolving fatty acids, carbohydrates and amino acids metabolism. This vitamin is also capable to form high-affinitybonds with various molecules, including streptavidin and avidin, which are essential components of manyimmunoassays based on the principle of biotin-streptavidin or biotin-avidin binding. In patients assuming high dosesof biotin, therefore, some competitive and non-competitive immunoassays may exhibit falsely increased and falselydecreased test results, respectively, with magnitude of interference depending on biotin concentration in the testsample and on specific vulnerability of the immunoassay. With the aim to provide some expert guidance foridentifying, preventing and managing biotin interference in clinical laboratory practice, this document contains a seriesof consensus recommendations endorsed by the Working Group on Extra-Analytical Variability of the Italian Societyof Clinical Chemistry and Clinical Molecular Biology (SIBioC). Briefly, the most important recommendationsencompass local evaluation of possible biotin interference, routine history taking on biotin intake for both inpatientsand outpatients, informing clinicians on potentially biotin-sensitive immunoassays, sample retesting 24-48 hours afterthe last biotin administration, along with possible consideration to add a note in the laboratory report highlighting themethods more vulnerable to biotin interference. Routine biotin measurement in all samples is currently discouraged.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967